Review Article
The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma
Table 3
Studies of HDT/ASCT in unfavorable DLBCL patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Plus radiotherapy at bulky disease. 2Plus radiotherapy at bulky disease and intrathecal prophylaxis in very high-risk patients. #See [26]. REAL: revised European-American lymphoma classification; WHO: World Health Organization classification of NHL; R: rituximab; (mega) CEOP: cyclophosphamide, epirubicin, vincristine, and prednisone; MAD: mitoxantrone, cytarabine, and dexamethasone; BEAM: carmustine, etoposide, cytarabine, and melphalan; CEEP: cyclophosphamide, epirubicin, vindesine, and prednisone; MTX: methotrexate; MC: methotrexate and cytarabine; ACBVP: doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; N.R.: not reported. |